<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Prescribing Advice for GPs</title>
	<atom:link href="http://www.prescriber.org.uk/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.prescriber.org.uk</link>
	<description>An NHS Prescribing Advisers&#039; Blog</description>
	<lastBuildDate>Wed, 28 Jul 2010 08:44:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>NICE Guidance &#8211; July 2010</title>
		<link>http://www.prescriber.org.uk/2010/07/nice-guidance-july-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/07/nice-guidance-july-2010/#comments</comments>
		<pubDate>Wed, 28 Jul 2010 08:44:06 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=959</guid>
		<description><![CDATA[The National Institute of Health and Clinical Excellence has published new guidance for the month of July 2010. This month there is a clinical guideline and public health guidance that have an impact on primary care. The clinical guideline details the care of adults with, or at risk of, delirium in hospital and in long-term [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/nice-guidance-july-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lipitor tablets getting smaller</title>
		<link>http://www.prescriber.org.uk/2010/07/lipitor-tablets-getting-smaller/</link>
		<comments>http://www.prescriber.org.uk/2010/07/lipitor-tablets-getting-smaller/#comments</comments>
		<pubDate>Mon, 26 Jul 2010 12:58:52 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=958</guid>
		<description><![CDATA[The manufacturer of atorvastatin (Lipitor&#174;) has written to doctors informing them that smaller round tablets will replace the existing oval shaped tablets across the range of strengths for atorvastatin. A change in the manufacturing process has allowed the tablets to be made smaller. There will also be some changes to the tablet markings and the [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/lipitor-tablets-getting-smaller/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MeReC Bulletin &#8211; Advanced Wound Dressings</title>
		<link>http://www.prescriber.org.uk/2010/07/merec-bulletin-advanced-wound-dressings/</link>
		<comments>http://www.prescriber.org.uk/2010/07/merec-bulletin-advanced-wound-dressings/#comments</comments>
		<pubDate>Thu, 22 Jul 2010 12:12:06 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=957</guid>
		<description><![CDATA[The National Prescribing Centre (NPC) has published a MeReC Bulletin (PDF) that reviews the evidence for the evidence based prescribing for advanced wound dressings (A2RA). This bulletin reviews the evidence based for advanced wound dressings noting that lack of high-quality studies using clinically relevant endpoints. It is also noted that there is no robust clinical [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/merec-bulletin-advanced-wound-dressings/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BNF for Children 2010-2011</title>
		<link>http://www.prescriber.org.uk/2010/07/bnf-for-children-2010-2011/</link>
		<comments>http://www.prescriber.org.uk/2010/07/bnf-for-children-2010-2011/#comments</comments>
		<pubDate>Wed, 21 Jul 2010 08:49:09 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=956</guid>
		<description><![CDATA[The British National Formulary for Children 2010-2011 has been updated, published and made available online. Hard copies can be ordered from the publishers however many NHS staff will receive a free hard copy through usual channels and can also access the online version at http://www.bnfc.nhs.uk. Update prescribing information in this revision include: Equivalent doses of [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/bnf-for-children-2010-2011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA to review ARB cancer link</title>
		<link>http://www.prescriber.org.uk/2010/07/fda-to-review-arb-cancer-link/</link>
		<comments>http://www.prescriber.org.uk/2010/07/fda-to-review-arb-cancer-link/#comments</comments>
		<pubDate>Mon, 19 Jul 2010 10:52:47 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=955</guid>
		<description><![CDATA[The Food and Drugs Administration (FDA) has announced that it is conducting a safety review of angiotensin receptor blockers (ARBs) after a recently published study suggested they may be associated with an increased risk of cancer. This announcement clarifies that: FDA&#8217;s review is ongoing and the Agency has not concluded that ARBs increase the risk [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/fda-to-review-arb-cancer-link/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SMC Update &#8211; July 2010</title>
		<link>http://www.prescriber.org.uk/2010/07/smc-update-july-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/07/smc-update-july-2010/#comments</comments>
		<pubDate>Thu, 15 Jul 2010 08:30:32 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=949</guid>
		<description><![CDATA[The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines. Sitagliptin (Januvia&#174;) has been accepted for restricted use as monotherapy to improve glycaemic control in patients with type 2 diabetes mellitus who are inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. Ketoprofen/omeprazole [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/smc-update-july-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CKS Update &#8211; July 2010</title>
		<link>http://www.prescriber.org.uk/2010/07/cks-update-july-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/07/cks-update-july-2010/#comments</comments>
		<pubDate>Wed, 14 Jul 2010 09:27:36 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=948</guid>
		<description><![CDATA[Clinical Knowledge Summaries (CKS) has been updated in July 2010 for the following clinical areas: Polycythaemia/erythrocytosis (new) Post-traumatic stress disorder (new) Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/cks-update-july-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>EMA starts rosiglitazone review</title>
		<link>http://www.prescriber.org.uk/2010/07/ema-starts-rosiglitazone-review/</link>
		<comments>http://www.prescriber.org.uk/2010/07/ema-starts-rosiglitazone-review/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 11:22:34 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=947</guid>
		<description><![CDATA[The European Medicines Agency has announced that it has started a review to determine whether new data on the risk of cardiovascular problems have an impact on the benefit-risk profile. Rosiglitazone is available in the European Union as a single agent (Avandia&#174;) and also in combination with metformin (Avandamet&#174;) and glimepiride (Avaglim&#174;). In 2008 a [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/ema-starts-rosiglitazone-review/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Influenza immunisation programme 2010/11 amendment</title>
		<link>http://www.prescriber.org.uk/2010/07/influenza-immunisation-programme-201011-amendment/</link>
		<comments>http://www.prescriber.org.uk/2010/07/influenza-immunisation-programme-201011-amendment/#comments</comments>
		<pubDate>Fri, 09 Jul 2010 10:54:05 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=946</guid>
		<description><![CDATA[The Chief Medical Officer at the Department of Health has reissued (PDF) an amended to colleagues within the NHS to provide details of the recommended influenza immunisation programme for 2010/11. The letter has been reissued to correct an error around the age below which children that have not previously received a seasonal influenza vaccine should [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/influenza-immunisation-programme-201011-amendment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Safety Update &#8211; July 2010</title>
		<link>http://www.prescriber.org.uk/2010/07/drug-safety-update-july-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/07/drug-safety-update-july-2010/#comments</comments>
		<pubDate>Thu, 08 Jul 2010 08:48:45 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=945</guid>
		<description><![CDATA[The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for July 2010 (PDF). This issue contains drug safety advice relating to the risk of accidental overdose with intravenous paracetamol (Perfalgan&#174;). While this product is not likely to be widely used in primary care, clinicians should be aware of the risks and [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/drug-safety-update-july-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>STI rates among users of ED drugs</title>
		<link>http://www.prescriber.org.uk/2010/07/sti-rates-among-users-of-ed-drug/</link>
		<comments>http://www.prescriber.org.uk/2010/07/sti-rates-among-users-of-ed-drug/#comments</comments>
		<pubDate>Tue, 06 Jul 2010 12:37:24 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=944</guid>
		<description><![CDATA[The Annals of Internal Medicine has published the results of an analysis of a medical claims database of private, employer-based insurance in 44 large companies to assess the association between usage of medication to treat erectile dysfunction and sexually transmitted infections (STI). The analysis identified claims made between 1997 and 2006 for 1,410,806 men older [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/07/sti-rates-among-users-of-ed-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Additional CKS Update &#8211; June 2010</title>
		<link>http://www.prescriber.org.uk/2010/06/additional-cks-update-june-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/06/additional-cks-update-june-2010/#comments</comments>
		<pubDate>Wed, 30 Jun 2010 08:10:31 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=943</guid>
		<description><![CDATA[Clinical Knowledge Summaries (CKS) has been further updated in June 2010 for the following clinical areas: Crohn&#8217;s disease (new) Ulcerative colitis (new) Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/06/additional-cks-update-june-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Additional NICE Guidance &#8211; June 2010</title>
		<link>http://www.prescriber.org.uk/2010/06/additional-nice-guidance-june-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/06/additional-nice-guidance-june-2010/#comments</comments>
		<pubDate>Tue, 29 Jun 2010 08:40:17 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=942</guid>
		<description><![CDATA[The National Institute of Health and Clinical Excellence has published additional new guidance for the month of June 2010. Earlier this month guidance was issued relating to alcohol-use disorders and reducing alcohol related harm. NICE has now issued further public health guidance relating to quitting smoking in pregnancy and following childbirth (QRG) and prevention of [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/06/additional-nice-guidance-june-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mixtard 30 being discontinued</title>
		<link>http://www.prescriber.org.uk/2010/06/mixtard-30-being-discontinued/</link>
		<comments>http://www.prescriber.org.uk/2010/06/mixtard-30-being-discontinued/#comments</comments>
		<pubDate>Mon, 28 Jun 2010 08:06:33 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=940</guid>
		<description><![CDATA[The manufacturer of Mixtard&#174; 30 has announced that this product will be discontinued by the 31st December 2010 due to declining demand. Mixtard 30 is the only remaining Mixtard preparation since the discontinuation of the other presentations in 2007. Patients are being advised to contact their doctor or nurse to discuss treatment options. This move [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/06/mixtard-30-being-discontinued/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NICE Guidance &#8211; June 2010</title>
		<link>http://www.prescriber.org.uk/2010/06/nice-guidance-june-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/06/nice-guidance-june-2010/#comments</comments>
		<pubDate>Thu, 17 Jun 2010 10:54:25 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=939</guid>
		<description><![CDATA[The National Institute of Health and Clinical Excellence has published new guidance for the month of June 2010. This month there is a clinical guideline and public health guidance that have an impact on primary care. The clinical guideline details the management of physical complications arising from alcohol-use disorders in adults and young people while [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/06/nice-guidance-june-2010/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>CKS Update &#8211; June 2010</title>
		<link>http://www.prescriber.org.uk/2010/06/cks-update-june-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/06/cks-update-june-2010/#comments</comments>
		<pubDate>Wed, 16 Jun 2010 08:32:27 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=938</guid>
		<description><![CDATA[Clinical Knowledge Summaries (CKS) has been updated in June 2010 for the following clinical areas: Haematospermia (new) Itch in pregnancy (new) Morton&#8217;s neuroma (new) Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/06/cks-update-june-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sinemet in short supply</title>
		<link>http://www.prescriber.org.uk/2010/06/sinemet-in-short-supply/</link>
		<comments>http://www.prescriber.org.uk/2010/06/sinemet-in-short-supply/#comments</comments>
		<pubDate>Tue, 15 Jun 2010 08:09:35 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=937</guid>
		<description><![CDATA[The manufacturer of Sinemet&#174; and Sinemet CR&#174; has written to healthcare professionals advising of a global supply shortage of these products. Pharmacies have also been made aware of this situation. The letter indicates that the shortage is as a consequence of a change in the source of supply of levodopa, one of the active ingredients [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/06/sinemet-in-short-supply/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ARB cancer link</title>
		<link>http://www.prescriber.org.uk/2010/06/arb-cancer-link/</link>
		<comments>http://www.prescriber.org.uk/2010/06/arb-cancer-link/#comments</comments>
		<pubDate>Mon, 14 Jun 2010 11:23:46 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=936</guid>
		<description><![CDATA[The Lancet Oncology has published the results of a meta-analysis that aimed to assess the association between angiotensin receptor blockers (ARBs) and the risk of cancer. This study has been reported in the general media (BBC). This analysis included studies involving one of the seven currently licensed ARBs provided that the study lasted for more [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/06/arb-cancer-link/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Influenza immunisation programme 2010/11</title>
		<link>http://www.prescriber.org.uk/2010/06/influenza-immunisation-programme-201011/</link>
		<comments>http://www.prescriber.org.uk/2010/06/influenza-immunisation-programme-201011/#comments</comments>
		<pubDate>Tue, 08 Jun 2010 08:48:10 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=935</guid>
		<description><![CDATA[The Chief Medical Officer at the Department of Health has written (PDF) to colleagues within the NHS to provide details of the recommended influenza immunisation programme for 2010/11. The letter provides details of the uptake for the seasonal and H1N1 vaccines for the 2009/10 campaign and also outlines the programme for 2010/11 providing details of: [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/06/influenza-immunisation-programme-201011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Safety Update &#8211; June 2010</title>
		<link>http://www.prescriber.org.uk/2010/06/drug-safety-update-june-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/06/drug-safety-update-june-2010/#comments</comments>
		<pubDate>Mon, 07 Jun 2010 10:11:34 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=934</guid>
		<description><![CDATA[The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for June 2010 (PDF). This issue contains drug safety advice relating to rivastigmine patches and quinine tablets. Rivastigmine (Exelon&#174;) patches are licensed for use in Alzheimer&#8217;s Dementia. Several issues have been reported in relation to the use of these patches resulting in [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/06/drug-safety-update-june-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescription charge changes delayed</title>
		<link>http://www.prescriber.org.uk/2010/05/prescription-charge-changes-delayed/</link>
		<comments>http://www.prescriber.org.uk/2010/05/prescription-charge-changes-delayed/#comments</comments>
		<pubDate>Fri, 28 May 2010 09:08:09 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=933</guid>
		<description><![CDATA[The Department of Health has announced that any further changes to the way prescriptions are charged or exempted will have to await the next Spending Review due in the Autumn. This decision has been reported in the general media (BBC). Since the 1st April 2009 patients on active cancer treatments have qualified for a medical [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/05/prescription-charge-changes-delayed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Falls prevented by single vision glasses</title>
		<link>http://www.prescriber.org.uk/2010/05/falls-prevented-by-single-vision-glasses/</link>
		<comments>http://www.prescriber.org.uk/2010/05/falls-prevented-by-single-vision-glasses/#comments</comments>
		<pubDate>Wed, 26 May 2010 10:05:40 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=932</guid>
		<description><![CDATA[The British Medical Journal has published the results of a study that aimed to assess whether the provision of single lens distance glasses to older wearers of multifocal glasses reduces falls. The results have been reported in the general media (BBC). The study was conducted in New South Wales, Australia and recruited 606 participants who [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/05/falls-prevented-by-single-vision-glasses/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SMC Update &#8211; May 2010</title>
		<link>http://www.prescriber.org.uk/2010/05/smc-update-may-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/05/smc-update-may-2010/#comments</comments>
		<pubDate>Fri, 21 May 2010 14:56:35 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=931</guid>
		<description><![CDATA[The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines. Telmisartan (Micardis&#174;) has been rejected for use in cardiovascular prevention and in type 2 diabetes with documented target organ damage. The manufacturer failed to make a submission. Sitagliption / Metformin (Janumet&#174;) has been accepted for restricted use as an adjunct to diet [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/05/smc-update-may-2010/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>MeReC Extra 45</title>
		<link>http://www.prescriber.org.uk/2010/05/merec-extra-45/</link>
		<comments>http://www.prescriber.org.uk/2010/05/merec-extra-45/#comments</comments>
		<pubDate>Thu, 20 May 2010 12:15:46 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=930</guid>
		<description><![CDATA[The National Prescribing Centre has published MeReC Extra 45 (PDF) which contains information regarding recent study results that identified blood pressure variability as an independent risk factor for stroke and the relationship between blood glucose lowering and mortality in type 2 diabetes. The first section discusses the results of a recent study published in the [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/05/merec-extra-45/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NICE Guidance &#8211; May 2010</title>
		<link>http://www.prescriber.org.uk/2010/05/nice-guidance-may-2010/</link>
		<comments>http://www.prescriber.org.uk/2010/05/nice-guidance-may-2010/#comments</comments>
		<pubDate>Wed, 19 May 2010 10:13:09 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=929</guid>
		<description><![CDATA[The National Institute of Health and Clinical Excellence has published new guidance for the month of May 2010. This month there is one clinical guideline that has an impact on primary care. The management of lower urinary tract symptoms in men (QRG) gives clear recommendations on assessing, monitoring and treating lower urinary tract symptoms. The [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2010/05/nice-guidance-may-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
